Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections. The company announced it will soon ask the U.S. FDA and international regulators to authorize it. (Nov. 5)

Subscribe for more Breaking News: http://smarturl.it/AssociatedPress
Website: https://apnews.com
Twitter: https://twitter.com/AP
Facebook: https://facebook.com/APNews
Instagram: https://www.instagram.com/APNews/
​

You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/de6dea332fc24dcf97d557c7150a49ea